When was NuProbe founded?

NuProbe was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is NuProbe located?

NuProbe is headquartered in George Town, Cayman Islands.

How many employees does NuProbe have?

As of Jul 01, 2024, the latest employee count at NuProbe is 67.

Is NuProbe a funded company?

NuProbe is a funded company, having raised a total of $61M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 23, 2018.

When was the latest funding round of NuProbe?

NuProbe's latest funding was a $***** Series B round on Jan 11, 2021, with participation from 11 investors.

Where does NuProbe rank among its competitors?

NuProbe ranks 44th amongst 692 active competitors, of which 171 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Guardant Health, which secured $350M in Nov, 2025.

Who are the top competitors of NuProbe?

NuProbe's top competitors include Guardant Health, Natera and Myriad Genetics. Among them, Guardant Health secured the most recent funding round in November, 2025.

NuProbe - 2026 Company Profile, Team, Funding & Competitors

NuProbe is a series B company based in George Town (Cayman Islands), founded in 2016 by David Yu Zhang, Peng Yin, Yingshuang Chai, Victor Shi, Junfeng Luo and Yundi Chen. It operates as a Develops sensitive multiplex tool for QPCR. NuProbe has raised $61M in funding from investors like Sequoia Capital, Yonghua Capital and Serica Partners. The company has 692 active competitors, including 171 funded and 130 that have exited. Its top competitors include companies like Guardant Health, Natera and Myriad Genetics.

Company Details

NuProbe develops sensitive multiple tool for QPCR. The technology is a multiplexed platform for QPCR with Toehold probe design that allows for the detection of rare allele detection as thermodynamics-guided probe design enables discrimination of a single nucleotide variant. The technology finds application in cancer diagnostics, NIPT, and infectious disease screening, and other areas.

Website: nuprobe.com
Social

Key Metrics

Founded Year

2016

Location

George Town, Cayman Islands

Stage

Series B

Total Funding

$61M in 4 rounds

Latest Funding Round

Series B, Jan 11, 2021, $*****

Investors

Sequoia Capital & 15 more

Ranked

44^th among 692 active competitors

Employee Count

67 as on Jul 01, 2024

Similar Companies

Guardant Health & 849 more

View NuProbe's full profile

NuProbe has raised a total funding of $61M over 4 rounds. Its first funding round was on Apr 23, 2018. Its latest funding round was a Series B round on Jan 11, 2021 for $*****. 11 investors participated in its latest round. NuProbe has 16 institutional investors.

Here is the list of recent funding rounds of NuProbe:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 11, 2021	4050054	Series B	2803901	2911710	8182777	9019305
Sep 01, 2019	4360952	Grant (prize money)	8907425	4927766	8123721	HHS
Sep 30, 2018	5117150	Grant (prize money)	1957762	9640944	8409979	HHS

Access funding benchmarks and valuations. Sign up today!

View details of NuProbe's funding rounds and investors

The founders of NuProbe are David Yu Zhang, Peng Yin, Yingshuang Chai, Victor Shi, Junfeng Luo and Yundi Chen.

Here are the details of NuProbe's key team members:

David Yu Zhang: Co-Founder & Director of NuProbe and founder of 1 other company. They serve on the board of 1 company.
Contact Info: 1 email address
Peng Yin: Co-Founder of NuProbe and founder of 2 other companies, panOpen and Spear Bio.
Contact Info: 1 email address
Yingshuang Chai: Co-Founder of NuProbe.
Victor Shi: Co-Founder of NuProbe and founder of 1 other company.
Contact Info: 1 email address
Junfeng Luo: Co-Founder of NuProbe.

View details of NuProbe's Founder profiles and Board Members

NuProbe's employee count trend

NuProbe has 67 employees as of Jul 24. Here is NuProbe's employee count trend over the years:

Uncover NuProbe's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NuProbe include Guardant Health, Natera and Myriad Genetics. Here is the list of Top 10 competitors of NuProbe, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	Lightspeed Venture Partners, Sequoia Capital ... & 25 others	79/100
2nd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Foresite Capital & 17 others	77/100
3rd	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, New Venturetec & 6 others	72/100
4th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Deerfield, Google Ventures & 11 others	71/100
5th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	70/100
6th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Beyond Ventures, Ping An Ventures & 22 others	69/100
7th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
8th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
9th	Qiagen 1984, Venlo (Netherlands), Acquired	Provider of products and reagents for molecular diagnostic assays	-	Life Sciences Partners, Harmonic & 6 others	65/100
10th	Saga Diagnostics 2016, Morrisville (United States), Acquired	Provider of tests for detection and analysis of circulating tumor DNA	$17.9M	Hadean Ventures, Segulah Medical Acceleration ... & 11 others	64/100
44th	NuProbe 2016, George Town (Cayman Islands), Series B	Develops sensitive multiplex tool for QPCR	$61M	Rencent Capital, Sequoia Capital & 14 others	51/100